INFI News Alert Infinity Pharmaceuticals (INFI) 17.78 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Infinity Pharmaceuticals (INFI) 17.78 $INFI

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), TGTX: 18.25 (+0.74), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), AZN: 71.80 (-1.80), ABBV: 65.27 (-1.76), INFI: 17.78 (-0.21), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)

T-Cell Lymphomas - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wvfhz/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - arGEN-X - Bristol-Myers Squibb - Celgene - Cell Medica - Infinity Pharmaceuticals - Karyopharm Therapeutics - Kyowa Hakko Kirin - Nippon Kayaku - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - Pharma Mar - Pharmacyclics - Seattle Genetics - Sigma-Tau For more information visit http://www.researchandmarkets.com/research/2w..._lymphomas
INFI: 17.78 (-0.21), BMY: 58.75 (-0.93), NVS: 93.52 (-0.82), KPTI: 34.85 (+1.35), CELGZ: 3.51 (-0.03)

Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at the American Society of Hematology Annual Meeting
Business Wire - Tue Dec 09, 10:30AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated data from a Phase 1 monotherapy study of duvelisib (IPI-145), an inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a fatal type of blood cancer. In the study, duvelisib demonstrated an overall response rate of 72 percent, including a 33 percent complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies. In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma. These data were presented today at the 56th Annual Meeting of the American Society of Hematology (ASH).
INFI: 17.78 (-0.21)

Infinity Pharmaceuticals Has Returned 40.5% Since SmarTrend Recommendation (INFI)
Comtex SmarTrend(R) - Tue Dec 09, 9:09AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 4 months, Infinity Pharmaceuticals has returned 40.47% as of today's recent price of $15.80.
INFI: 17.78 (-0.21)

Infinity Reports New Translational Research and Updated Phase 1 Data of Investigational Oncology Compound Duvelisib at American Society of Hematology Annual Meeting
Business Wire - Mon Dec 08, 9:45AM CST
--- Updated Phase 1 Data Highlight Duvelisib Activity as a Monotherapy in Relapsed/Refractory Chronic Lymphocytic Leukemia -
INFI: 17.78 (-0.21)

Upgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Thu Dec 04, 6:55AM CST
Infinity Pharmaceuticals (NASDAQ:INFI) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $15.38 on volume of 764,000 shares, above average daily volume of 610,000. Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The Company uses small molecule drug technologies in the development of its products.
INFI: 17.78 (-0.21)

Shares of INFI Up 32.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 01, 4:43PM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 4 months, Infinity Pharmaceuticals has returned 32.77% as of today's recent price of $14.93.
INFI: 17.78 (-0.21)

Infinity Pharmaceuticals (INFI) Is Today's Strong On High Volume Stock
at The Street - Wed Nov 26, 9:02AM CST
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate
INFI: 17.78 (-0.21)

Infinity Pharmaceuticals Shares Up 26.3% Since SmarTrend's Buy Recommendation (INFI)
Comtex SmarTrend(R) - Mon Nov 24, 11:10AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 3 months, Infinity Pharmaceuticals has returned 26.32% as of today's recent price of $14.21.
INFI: 17.78 (-0.21)

Post Earnings Update: Infinity Pharmaceuticals Has Climbed 17.1% Higher in Past 2 Weeks (INFI)
Comtex SmarTrend(R) - Mon Nov 24, 8:55AM CST
Two weeks ago on November 6th, 2014 Infinity Pharmaceuticals (NASDAQ:INFI) reported earnings and analysts, on average, expected earnings of $1.26 on sales of $137.5 million. Infinity Pharmaceuticals actually reported earnings of $2.03 per share on sales of $160.6 million, beating EPS estimates by $0.77 and beating revenue estimates by $23.1 million. Since the company's report, shares of Infinity Pharmaceuticals have risen from $12.14 to $14.21, representing a gain of 17.1% in the past 18 days.
INFI: 17.78 (-0.21)

Infinity to Present at the Deutsche Bank Securities 2014 BioFEST Conference
Business Wire - Mon Nov 24, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Deutsche Bank Securities 2014 BioFEST Conference on December 1, 2014 at 2:15 p.m. ET in Boston.
DB: 30.78 (-0.56), INFI: 17.78 (-0.21)

Infinity Pharmaceuticals Earnings In Retrospect: Up 16.1% in the Last 11 Days (INFI)
Comtex SmarTrend(R) - Mon Nov 17, 1:03PM CST
When Infinity Pharmaceuticals (NASDAQ:INFI) reported earnings 11 days ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $1.26 on sales of $137.5 million. Infinity Pharmaceuticals actually reported earnings of $2.03 per share on sales of $160.6 million, beating EPS estimates by $0.77 and beating revenue estimates by $23.1 million. Since the company's report, shares of Infinity Pharmaceuticals have risen from $12.14 to $14.10, representing a gain of 16.1% in the past 11 days.
INFI: 17.78 (-0.21)

Infinity Pharmaceuticals Has Returned 26.0% Since SmarTrend Recommendation (INFI)
Comtex SmarTrend(R) - Mon Nov 17, 10:19AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 3 months, Infinity Pharmaceuticals has returned 26.01% as of today's recent price of $14.17.
INFI: 17.78 (-0.21)

Infinity Pharmaceuticals (INFI) Is Strong On High Volume Today
at The Street - Fri Nov 14, 9:08AM CST
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate
INFI: 17.78 (-0.21)

Infinity Pharmaceuticals (INFI) Upgraded From Sell to Hold
at The Street - Fri Nov 14, 8:39AM CST
Infinity Pharmaceuticals (INFI) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
INFI: 17.78 (-0.21)

Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 5:14PM CST

INFI: 17.78 (-0.21)

Infinity beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 4:54PM CST
CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Thursday reported third-quarter net income of $103.2 million.
INFI: 17.78 (-0.21)

Infinity Pharmaceuticals (INFI) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST

INFI: 17.78 (-0.21)

Infinity Pharmaceuticals EPS of $2.03
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:19PM CST

INFI: 17.78 (-0.21)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading